Does Emtricitabine And Tenofovir Alafenamide Interact with Valganciclovir?
CDI records a moderate classification for Emtricitabine And Tenofovir Alafenamide and Valganciclovir. The stored summary is: Coadministration may increase concentrations of FTC, tenofovir, and valganciclovir due to competition for active tubular secretion. The mechanism involves competition for renal active tubular secretion. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
Evidence status
A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.
Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.
- Stored CDI classification
- Moderate
- Emtricitabine And Tenofovir Alafenamide Class
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Valganciclovir Class
- Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
- Management
- Confirm exact products with your pharmacist
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Competition for renal active tubular secretion
What To Tell Your Doctor or Pharmacist
If you are taking Emtricitabine And Tenofovir Alafenamide and your doctor is considering prescribing Valganciclovir (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider